ARID1A-deficient Bladder Cancer is Dependent on PI3K Signaling, and can be Targeted via EZH2 and/or PI3K Pharmacologic Inhibition: Therapeutic Implications
Ontology highlight
ABSTRACT: ARID1A-mutant bladder cancer is dependent on PI3K signaling and is sensitive to EZH2 and/or PI3K inhibition. Clinical trials in molecularly selected patients should be considered.
ORGANISM(S): Homo sapiens
PROVIDER: GSE203033 | GEO | 2022/08/22
REPOSITORIES: GEO
ACCESS DATA